Dr. Robert Lenz Joins Unlearn as Strategic Advisor

Audio By Carbonatix

SAN FRANCISCO--(BUSINESS WIRE)--Sep 25, 2025--

Unlearn®, a leader in AI solutions for clinical trials, today welcomed Dr. Robert Lenz as a strategic advisor. Dr. Lenz brings over 20 years of global research and development leadership at companies including Amgen, AbbVie, and Neumora, and will advise Unlearn as it expands partnerships with sponsors and regulators. Having pioneered AI-generated digital twins of patients in clinical trials, Unlearn is now building on this foundation with a suite of advanced AI solutions that empower sponsors to accelerate development, optimize studies, and make more informed decisions.

“Rob’s career has been dedicated to advancing innovative development strategies at scale,” said Steve Herne, CEO of Unlearn. “His insight and leadership will be invaluable as Unlearn works with sponsors and regulators to bring AI-powered solutions into clinical development in ways that are rigorous, practical, and regulator-ready.”

Dr. Lenz joins Unlearn as an accomplished biopharmaceutical executive with decades of R&D expertise. Most recently, he served as Executive Vice President and Head of R&D at Neumora. Before that, he spent over a decade at Amgen, where he held senior roles, including Senior Vice President, Head of Global Development. At Amgen, he oversaw more than 130 interventional study starts, enrolling over 53,000 patients across 50+ countries, and played a key role in advancing innovative trial designs across the company’s portfolio. Earlier in his career, Dr. Lenz served as Divisional Vice President at Abbott, where he led neurology, psychiatry, and anesthesiology development.

“Unlearn’s approach represents one of the most compelling applications of AI in clinical development today,” said Dr. Lenz. “The company’s commitment to transparency, scientific rigor, and regulatory engagement sets it apart, and I’m excited to support the team as they work with sponsors to design smarter studies and make better development decisions.”

Dr. Lenz received his M.D. and Ph.D. with honors from the University of Maryland, with a research focus in Neuropharmacology. He completed his residency in Neurology at UCLA.

For more information about Unlearn, visit: www.unlearn.ai

About Unlearn
Unlearn ( www.unlearn.ai ) partners with leading pharma and biotech companies to bring AI into clinical development where it matters most: enabling more confident decision-making. At the core of our approach are Digital Twin Generators—AI models that forecast patient outcomes and provide trial-ready evidence sponsors can trust. By improving cross-functional alignment across biostatistics, clinical, and regulatory groups, Unlearn helps sponsors move programs forward with greater clarity. With deep regulatory engagement—including EMA qualification and FDA endorsement—Unlearn is transforming drug development to be faster, smarter, and more reliable.

For more information, visit www.unlearn.ai or follow us on LinkedIn and X/Twitter.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250925437584/en/

CONTACT: Alyssa Horowitz

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: TECHNOLOGY RESEARCH CLINICAL TRIALS HEALTH TECHNOLOGY BIOTECHNOLOGY HEALTH PHARMACEUTICAL SCIENCE ARTIFICIAL INTELLIGENCE

SOURCE: Unlearn

Copyright Business Wire 2025.

PUB: 09/25/2025 09:00 AM/DISC: 09/25/2025 08:59 AM

http://www.businesswire.com/news/home/20250925437584/en